A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

March 31, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

September 30, 2026

Conditions
Glioblastoma Multiforme
Interventions
DRUG

NanO2TM

0.1 mL/kg NanO2 infusion

DRUG

Placebo Saline Infusion

Saline Infusion

Trial Locations (12)

22031

Inova Schar Cancer Institute, Fairfax

27710

Duke University Medical Center, Durham

44106

University Hospitals Seidman Cancer Center, Cleveland

61637

St. Francis Medical Center, OSF Healthcare, Peoria

64111

Saint Luke's Cancer Institute, Kansas City

70121

Ochsner Clinic Foundation, New Orleans

85718

Center for Neurosciences, Tucson

85719

University of Arizona, Tucson

90404

Providence St. John's Cancer Institute, Santa Monica

92868

UC Irvine Health- Chao Family Comprehensive Cancer Center, Orange

06520

Yale Cancer Center, New Haven

07901

Atlantic Health System, Summit

All Listed Sponsors
lead

NuvOx LLC

INDUSTRY